drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous T cells genetically engineered to express a chimeric antigen receptor targeting CD19 on B cells, incorporating CD3ζ signaling with a costimulatory domain (e.g., CD28 or 4-1BB) to activate, expand, and mediate cytotoxic killing of malignant B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor with an anti‑CD19 binding domain linked to CD3ζ signaling and a costimulatory domain (e.g., CD28 or 4‑1BB). Binding to CD19 on B cells triggers MHC‑independent T‑cell activation, proliferation, cytokine release, and perforin/granzyme‑mediated cytotoxicity, leading to elimination of CD19+ malignant B cells and on‑target B‑cell aplasia.
drug_name
CD19-directed CAR T-cell therapy
nct_id_drug_ref
NCT07236203